Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
36 hedge funds and large institutions have $287K invested in Nymox Pharmaceutical Corp in 2023 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 3 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 35 → 36 (+1)
0% more call options, than puts
Call options by funds: $1K | Put options by funds: $1K
50% less capital invested
Capital invested by funds: $575K → $287K (-$288K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DDC
DF Dent & Co
Baltimore,
Maryland
|
+$29.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$13.4K |
| 3 |
LNC
Lincoln National Corp
Radnor,
Pennsylvania
|
+$4.42K |
| 4 |
VF
Virtu Financial
New York
|
+$2.78K |
| 5 |
JP Morgan Chase
New York
|
+$974 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$59.1K |
| 2 |
BlackRock
New York
|
-$38.2K |
| 3 |
Millennium Management
New York
|
-$16K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$13.9K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$3.77K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
JP Morgan Chase
New York
| $1.94K | +$974 | +2,475 | +32% |
|
|
CAM
27
Cubic Asset Management
Boston,
Massachusetts
| $1.9K | – | – | – |
|
|
GVAG
28
Great Valley Advisor Group
Wilmington,
Delaware
| $1.9K | – | – | – |
|
|
ODIJL
29
One Day In July LLC
Burlington,
Vermont
| $1.9K | – | – | – |
|
30
Group One Trading
Chicago,
Illinois
| $1.01K | +$26 | +67 | +1% |
|
|
BWA
31
BDO Wealth Advisors
Jacksonville,
Florida
| $893 | – | – | – |
|
32
Wells Fargo
San Francisco,
California
| $627 | – | – | – |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| $381 | +$539 | +1,369 | +215% |
|
34
BNP Paribas Financial Markets
Paris,
France
| $163 | – | – | – |
|
35
Bank of America
Charlotte,
North Carolina
| $134 | – | – | – |
|
|
36
Millennium Management
New York
| – | -$16K | -47,916 | Closed |
|
|
BAM
37
Belpointe Asset Management
Reno,
Nevada
| – | -$755 | -2,221 | Closed |
|
38
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$563 | +1,430 | New |
|
NYMX Hedge Fund Activity: Q2 2023 in Review
36 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q2 2023, worth a combined $287K — down 50% from $575K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new NYMX positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 5 trimmed.
The largest buyer was DF Dent & Co, opening a new position worth an estimated $29.5K. The largest seller was Federation des caisses Desjardins du Quebec, cutting an estimated $59.1K.
- 36 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q2 2023, up from 35 in Q1 2023.
- Funds reported $287K of Nymox Pharmaceutical Corp stock for Q2 2023, down 50% quarter-over-quarter.
- 4 funds opened new Nymox Pharmaceutical Corp positions in Q2 2023 and 3 closed out, a net change of +1 holder.
- The largest Nymox Pharmaceutical Corp buyer in Q2 2023 was DF Dent & Co, an estimated $29.5K added.
- The largest Nymox Pharmaceutical Corp seller in Q2 2023 was Federation des caisses Desjardins du Quebec, an estimated $59.1K sold.
Based on aggregated 13F filings for Q2 2023.